ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
University of Calgary Joins Trial of LSALT Peptide for Complications in Hospitalized COVID-19 Patients
January 12, 2021Arch Biopartners announced the University of Calgary Cumming School of Medicine has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications ... -
Therapix, University of Calgary to Evaluate Proprietary Drug Candidate for Pain
December 24, 2020Therapix Biosciences announced a collaboration between the company and The University of Calgary to further evaluate the analgesic effect of Therapix's CB2R agonist proprietary drug candidate, THX-160.
Pharma Sources Insight January 2025
